Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

FeliciaMath Dec. 6 at 3:54 PM

not selling $GNPX for less than 4.5. planning on making another 2500 profit towards my new VW Tiguan.

0 · Reply

Botaeng Dec. 6 at 9:11 AM

$GNPX even if it breaks out and starts running... Management will drop an offering before it can reach 10% of it's potential.

0 · Reply

BennyBjammin Dec. 5 at 11:29 PM

$GNPX High risk/reward. This hit $55 50 days ago and is now sitting at $3.40. Needs to dig out of the downward channel (purple). Good news is that price is respecting the bottom trendline; bad news is that the trendline is steep. Price is currently on the handle of a Cup and Handle in the downward channel... flip a coin.

1 · Reply

TheRoaringBunny Dec. 5 at 11:13 PM

$BULL $GNPX $PLBY $VG $XPON You have less than 2 hours to grab $PLBY The next global meme stock runs on Monday

0 · Reply

TheRoaringBunny Dec. 5 at 11:07 PM

$ARBK $GNPX $NVNI $QS Dump the duds and grab $PLBY Get the next global meme stock while you still can. Less than 2 hours left

0 · Reply

ACInvestorBlog Dec. 5 at 11:06 PM

$GNPX small bio cap finally showing some love (low float).

1 · Reply

Csteele Dec. 5 at 2:43 PM

$GNPX needs volume and needs to break 3.6 or it will pitter out for a bit

0 · Reply

Mazen79 Dec. 5 at 1:19 PM

$GNPX if it have a good volume above 3.8 today I am in for next week

0 · Reply

rick4u Dec. 5 at 1:16 PM

$GNPX gogogo

0 · Reply

Tradingistheway Dec. 5 at 9:12 AM

$GNPX did this RS

1 · Reply

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 19, 2025, 7:00 AM EST - 17 days ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 18, 2025, 7:00 AM EST - 18 days ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Oct 28, 2025, 11:19 AM EDT - 5 weeks ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 7:00 AM EDT - 5 weeks ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:12 AM EDT - 6 weeks ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 6 weeks ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 3 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 3 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 4 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 5 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 5 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 6 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 6 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 6 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 7 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 7 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 7 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 8 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 8 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 9 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 9 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 9 months ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 10 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 10 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 10 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 11 months ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 11 months ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

May 30, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present at the 2024 BIO International Convention

May 14, 2024, 8:31 AM EDT - 1 year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

FeliciaMath Dec. 6 at 3:54 PM

not selling $GNPX for less than 4.5. planning on making another 2500 profit towards my new VW Tiguan.

0 · Reply

Botaeng Dec. 6 at 9:11 AM

$GNPX even if it breaks out and starts running... Management will drop an offering before it can reach 10% of it's potential.

0 · Reply

BennyBjammin Dec. 5 at 11:29 PM

1 · Reply

TheRoaringBunny Dec. 5 at 11:13 PM

$BULL $GNPX $PLBY $VG $XPON You have less than 2 hours to grab $PLBY The next global meme stock runs on Monday

0 · Reply

TheRoaringBunny Dec. 5 at 11:07 PM

$ARBK $GNPX $NVNI $QS Dump the duds and grab $PLBY Get the next global meme stock while you still can. Less than 2 hours left

0 · Reply

ACInvestorBlog Dec. 5 at 11:06 PM

$GNPX small bio cap finally showing some love (low float).

1 · Reply

Csteele Dec. 5 at 2:43 PM

$GNPX needs volume and needs to break 3.6 or it will pitter out for a bit

0 · Reply

Mazen79 Dec. 5 at 1:19 PM

$GNPX if it have a good volume above 3.8 today I am in for next week

0 · Reply

rick4u Dec. 5 at 1:16 PM

$GNPX gogogo

0 · Reply

Tradingistheway Dec. 5 at 9:12 AM

$GNPX did this RS

1 · Reply

TheRoaringBunny Dec. 5 at 4:37 AM

$BITF $GNPX $HOLO $IRBT $NAK GNPX multi day really $8.50 PT

0 · Reply

Stock_Catcher Dec. 5 at 3:40 AM

Fortune Friday Watchlist Pt. 8 $HOLO $BITF $NAK $GNPX $IRBT Let's Bank Tomorrow ✅

0 · Reply

Csteele Dec. 5 at 1:15 AM

$GNPX could this be a little push to open the densly compressed bollinger bands in prepearsrion to explode. May slide the next few days, I’m very curious. It’s not going to 50, but could see a sigbificant move in the coming days.

1 · Reply

TheRoaringBunny Dec. 4 at 11:55 PM

$BULL $GNPX $PLBY $TSSI $VG Correction: TSSI and Dell are NOT exclusive They do fornicate with others, but fornicate with each other often as well. Per grok - Approximately 100% of TSS Inc.‘s (TSSI) revenue in Q3 2025 came from Dell Technologies, as reported in the company’s earnings release and analyst coverage. This reflects heavy reliance on their multi-year AI rack integration partnership, though TSSI serves other clients like Microsoft and Walmart. For the full year 2025 (ending December), the exact percentage isn’t detailed in available reports, but Q2 2025 showed 97% from Dell, indicating sustained dominance. TSSI’s total 2025 revenue through Q3 reached about $231 million, up significantly year-over-year.

0 · Reply

TheRoaringBunny Dec. 4 at 11:17 PM

BIG movers for Friday, or maybe Thursday night! $PLBY meme now ask questions later PT $7.50 $GNPX politician tail, Tim Moores avg is $5-6, PT $7.50 $VG natural gas exporter with new Japan contract PT $15 $TSSI is Dells exclusive AI datacenter partner rebound PT $20 $BULL is the Sofi Killer eyeing a quick $10.50 gap fill before heading to $15 🐰🐇🐰🐇🐰

1 · Reply

Mg_1970 Dec. 4 at 8:37 PM

$GNPX Stop loss? No...I had no stop loss

1 · Reply

TheRoaringBunny Dec. 4 at 8:21 PM

$GNPX if tim can hodl Then you can hold too Hodl for tim $7.50

0 · Reply

Csteele Dec. 4 at 8:06 PM

$GNPX happy hour, will she run AH

0 · Reply

TheRoaringBunny Dec. 4 at 7:34 PM

$PLBY $VG $GNPX $BULL $XPON Power hour / after hours runners

0 · Reply

Shortsalwayswin Dec. 4 at 6:02 PM

$GNPX too easy

1 · Reply

TheRoaringBunny Dec. 4 at 5:58 PM

$GNPX $SMX

0 · Reply

rick4u Dec. 4 at 5:54 PM

$GNPX all in. Big New coming

2 · Reply

Market Cap	7.77M
Revenue (ttm)	0.00
Net Income (ttm)	-21.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	300,800
Avg Vol	877,347
Day's Range	N/A - N/A
Shares Out	2.32M
Stochastic %K	70%
Beta	-0.77
Analysts	Strong Buy
Price Target	$375.00